2026-01-24 - Analysis Report
**Company Overview:** Huntington Ingalls is a leading designer and builder of nuclear and non-nuclear ships for the U.S. Navy and other customers.

**Return Rate Comparison:**

* Cumulative return of review stock (HII): 128.24%
* Cumulative return of comparison stock (S&P 500, VOO): 126.41%
* Divergence: 1.83%
* Relative divergence: 78.70%

The review stock has outperformed the comparison stock, indicating a higher return rate. However, the divergence is relatively low, suggesting that the difference in performance may be due to other factors.

**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2016-2018  | 0.0% | 28.7% | -12.0% | 0.9 | 7.5B |
| 2017-2019  | 3.0% | 28.7% | -22.0% | 1.0 | 9.8B |
| 2018-2020  | -45.0% | 42.6% | -69.0% | 0.9 | 6.7B |
| 2019-2021  | -8.0% | 42.6% | -74.0% | 0.8 | 7.3B |
| 2020-2022  | -10.0% | 41.7% | -17.0% | 0.7 | 9.1B |
| 2021-2023  | 57.0% | 19.6% | 37.0% | 0.5 | 10.2B |
| 2022-2024  | 0.0% | 34.0% | -30.0% | 0.6 | 7.4B |
| 2023-2025  | 64.0% | 40.5% | -11.0% | 0.7 | 13.3B |

The review stock has shown varying levels of performance across different periods, with some periods experiencing high returns and others experiencing losses.

**Recent Stock Price Fluctuations:**

* Close: $418.58
* Last-market change: -1.31%
* 5-day SMA: $421.38
* 20-day SMA: $384.41
* 60-day SMA: $339.23

The review stock's price has been fluctuating, with the 5-day SMA being higher than the current price, suggesting a recent decline.

**RSI, PPO Index Indicators, and Delta:**

* Market Risk Indicator (MRI): 0.70
* RSI: 78.00
* PPO: 0.42
* Hybrid Signal: Buy (Cash 0%)
* Risk Level: Medium (MRI 0.70)
* Recent (20 days) relative divergence change: 0.50 (+): improving
* 7-day Rank change: 45 (+): rank up
* 7-day Dynamic Expected Return change: -10.40 (-): worsening
* Expected Return: -17.50%

The review stock is showing signs of improvement, with a higher RSI and PPO index values. However, the expected return is negative, indicating potential risks.

**News & Significant Events:**

* 2026-01-23: Is Huntington Ingalls (HII) Priced Fairly After A 113% One Year Surge?
* 2026-01-12: What You Need To Know Ahead of Huntington Ingalls' Earnings Release
* 2026-01-21: Analysts see 14% downside to Huntington Ingalls Industries, Inc. (HII)
* 2026-01-20: Lobbying Update: $1,580,000 of HUNTINGTON INGALLS INDUSTRIES INCORPORATED lobbying was just disclosed
* 2026-01-15: Here's Why You Should Add HII Stock to Your Portfolio Right Now
* 2026-01-21: US Navyâ€™s first hypersonic warship clears key sea trials

These news events may have an impact on the review stock's performance.

**Analyst Opinions:**

Analyst Consensus:
- Key: Buy
- Mean (1=StrongBuy~5=Sell): 2.45 (~Buy)
- Opinions: 10
- Target Price (avg/high/low): 380.60 / 450.00 / 292.00

The overall analyst consensus is to buy the review stock, with a target price range of $292.00 to $450.00.

**Recent Earnings Analysis:**

| Date | EPS | Revenue |
|---|---:|---:|
| 2025-10-30 | 3.69 | 3.19 B$ |
| 2025-07-31 | 3.86 | 3.08 B$ |
| 2025-05-01 | 3.79 | 2.73 B$ |
| 2024-10-31 | 2.56 | 2.75 B$ |
| 2025-10-30 | 2.56 | 2.75 B$ |

The review stock's earnings have been steadily increasing, with the most recent quarter showing an EPS of $3.69 and revenue of $3.19 billion.

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $3.19B | 12.34% |
| 2025-06-30 | $3.08B | 12.82% |
| 2025-03-31 | $2.73B | 14.41% |
| 2024-12-31 | $3.00B | 10.69% |
| 2024-09-30 | $2.75B | 11.71% |

The review stock's revenue has been steadily increasing, with the most recent quarter showing a revenue of $3.19 billion and a profit margin of 12.34%.

**Capital and Profitability:**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $4.98B | 2.91% |
| 2025-06-30 | $4.88B | 3.11% |
| 2025-03-31 | $4.77B | 3.12% |
| 2024-12-31 | $4.67B | 2.64% |
| 2024-09-30 | $4.20B | 2.40% |

The review stock's equity has been steadily increasing, with the most recent quarter showing an equity of $4.98 billion and a return on equity (ROE) of 2.91%.

**Comprehensive Analysis:**

The review stock has shown a high level of return rate, with a cumulative return of 128.24%. The stock's price has been fluctuating, with the 5-day SMA being higher than the current price, suggesting a recent decline. The RSI and PPO index values are high, indicating a potential buying opportunity. However, the expected return is negative, indicating potential risks. The recent earnings analysis shows a steadily increasing EPS and revenue, with a profit margin of 12.34%. The equity has been steadily increasing, with an ROE of 2.91%. Overall, the review stock appears to be a medium-risk investment, with a potential for high returns. However, it is essential to consider the individual's risk tolerance and investment goals before making any investment decisions.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.